Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has enticing clinical potential that has caught the eyes of more than one bull who have sounded off on this biotech firm’s meaningful potential. One enthusiastic voice comes from H.C. Wainwright analyst Ed Arce who sees a lot to look forward to down the line with Aurinia’s not-so-secret weapon: voclosporin.
H.C. Wainwright Likes Aurinia Pharmaceuticals’ Opportunity at Hand in the Lupus Nephritis Market
